期刊文献+

高效液相色谱-荧光检测法测定瑞格列奈片含量及其溶出度研究 被引量:2

Dissolution and Content Determination of Repaglinide Tablets by HPLC-Fluorescence Detection
原文传递
导出
摘要 目的:建立测定痕量瑞格列奈的方法,并用于瑞格列奈片的溶出度研究。方法:采用高效液相色谱-荧光检测法。色谱柱为C18,流动相为0.5%磷酸(pH调至2.5)-甲醇-乙腈(40∶10∶50),流速为1.0mL·min-1,柱温为40℃,进样量为20μL,荧光检测波长为λex=244nm、λem=348nm。溶出度测定方法为桨法,溶出介质为枸橼酸-磷酸盐缓冲液(pH=5.0),转速为75r·min-1,测定3批片剂在60min内的累积溶出度。结果:瑞格列奈检测浓度线性范围为0.055~1.76μg·mL-1(r=0.9997),低、中、高浓度平均回收率分别为98.8%、99.4%、99.6%(RSD=1.4%、1.3%、1.5%),最低定量限0.21ng,最低检测限0.05ng。3批片剂30min时累积溶出度为89.6%~93.4%。结论:该方法灵敏度高、专属性强,适用于瑞格列奈的痕量测定及满足大杯法研究瑞格列奈片的溶出度的要求。 OBJECTIVE: To establish the method for the trace determination and dissolution study of Repaglinide tablets. METH- ODS: HPLC-fluorescence detection was adopted. A separation was performed on Kromasil C18 column, the mobile phase was 0.5% phosphonic acid (pH adjusted to 2.5)-methanol-acetonitrile (40 : 10 : 50) with the flow rate at 1.0 mL. min 1. The column temperature was 40 ℃and injection volume 20 μL. The wavelengths of excitation and emission were set at 244 nm and 348 nm, respectively. The dissolution of Repaglinide tablets was detected by paddle method using citric acid-phosphate buffer solution (pH= 5.0) as solvent at rotation speed of 75 r. min^-1. The accumulative dissolution of 3 batches of samples was determined. RESULTS: The linear range of repaglinide was 0.055~1.76 μg.mL^-1 (r=0.999 7) with average recoveries of 98.8%, 99.4% and 99.6% at low, medium and high concentration (RSD= 1.4%, 1.3%, 1.5% ). The quantitative limit was 0.21 ng and detection limit was 0.05 ng. The accumulative dissolution of 3 batches of samples at 30 min was 89.6 % ~93.4 %. CONCLUSION: The method is sensitive and specific for the trace determination and dissolution of repaglinide.
出处 《中国药房》 CAS CSCD 北大核心 2011年第9期841-843,共3页 China Pharmacy
关键词 瑞格列奈片 痕量测定 高效液相色谱-荧光检测法 累积溶出度 Repaglinide tablets Trace determination HPLC-fluorescence detection Accumulative dissolution
  • 相关文献

参考文献6

二级参考文献24

  • 1吴志强,李怡辉.关于药物溶出度自身对照法应用的探讨[J].海峡药学,2004,16(5):63-66. 被引量:4
  • 2王淑梅,殷立新,樊德厚,王晓明.国内药物制剂溶出度试验品种介绍(续四)[J].中国医院药学杂志,2005,25(6):560-564. 被引量:4
  • 3谢沐风.改善溶出度评价方法,提高固体药物制剂水平[J].中国医药工业杂志,2005,36(7):447-451. 被引量:126
  • 4樊德厚,苏春平,赵合兴,任进民,王川平,王春英,黄慧英.国内药物制剂溶出度试验品种介绍(续一)[J].中国医院药学杂志,1996,16(5):225-228. 被引量:7
  • 5DECODA Study Group,International Diabetes Epidemiology Group.Cardiovascular risk profile assessment in glucose-intolerant Asian individuals-an evaluation of the World Health Organization two-step strategy:the DECODA Study (Diabetes Epidemiology:Collaborative Analysis of Diagnostic Criteria in Asia).Diabet Med,2002,19:549-557.
  • 6Consequences of the new diagnostic criteria for diabetes in older men and women.DECODE Study (Diabetes Epidemiology:Collaborative Analysis of Diagnostic Criteria in Europe).Diabetes Care,1999,22:1667-1771.
  • 7International Diabetes Federation.Guideline for management of postmeal glucose.2007.
  • 8Monnier L,Lapinski H,Colette C.Contributions of fasting and postprandial plasma glucose increments to the overall diurnal hyperglycemia of type 2 diabetic patients:variations with increasing levels of HbA (1c).Diabetes Care,2003,26:881-885.
  • 9Service FJ,O'Brien PC.The relation of glycaemia to the risk of development and progression of retinopathy in the diabetic control and complications trial.Diabetologia,2001,44:1215-1220.
  • 10Monnier L,Mas E,Ginet C,et al.Activation of oxidative stress by acute glucose fluctuations compared with sustained chronic hyperglycemia in patients with type 2 diabetes.JAMA,2006,295:1681-1687.

共引文献15

同被引文献14

引证文献2

二级引证文献5

相关作者

内容加载中请稍等...

相关机构

内容加载中请稍等...

相关主题

内容加载中请稍等...

浏览历史

内容加载中请稍等...
;
使用帮助 返回顶部